

Special Issue

Vaccine Efficacy and Safety in People with Kidney Diseases/Kidney Transplant Recipients

Message from the Guest Editor

The COVID-19 pandemic unmasked the impact of extrinsic immunosuppression, as in kidney transplant recipients, or intrinsic immunosuppression, as in ESRD patients with chronic inflammation and immune senescence with exceptionally high lethality. Immunocompromised cohorts with kidney diseases have a significantly impaired SARS-CoV-2 vaccine response compared with healthy subjects, even to new mRNA vaccines. With the upcoming different Omicron variants characterized by immune escape, novel vaccination strategies, including adapted mRNA vaccines against epitopes of emerging variants, are needed to protect high-risk individuals. However, further research is needed to fully understand the efficacy and safety of these bivalent vaccines against emerging variants. This Special Issue specifically welcomes (1) the submission of manuscripts that address efficacy, immunogenicity, and long-term immune response after bivalent COVID-19 vaccination, and (2) studies of non-COVID-19 vaccines that examine humoral and cellular immunity to various vaccines in immunocompromised individuals with kidney disease.

Guest Editor

Dr. Claudius Speer

Department of Nephrology, Heidelberg University Hospital, 69120 Heidelberg, Germany

Deadline for manuscript submissions

closed (31 January 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/180961

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).